{
    "clinical_study": {
        "@rank": "15049", 
        "arm_group": {
            "arm_group_label": "Mercury, Aluminum or Palladium Subjects", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will be patch tested with  ascending doses of mercury, aluminum or palladium and a negative control and a second panel containing the marketed reference allergen. The panels will be worn for approximately 48 hours. Skin reactions will be assessed at 3, 4 and 21 days following application."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare ascending doses of investigational T.R.U.E. Test\n      allergens to the marketed petrolatum reference allergen."
        }, 
        "brief_title": "Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Contact Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Contact"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single-center, double-blind, randomized study to compare the diagnostic\n      performance (primary) and safety (secondary) of ascending doses of mercury, aluminum and\n      palladium in 20 adult subjects who have a clinical history of contact dermatitis and have\n      tested positive (current or previous patch test) to at least one of the allergens being\n      tested."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.15 years of age or older.\n\n        2. History of contact dermatitis.\n\n        3. Positive patch results to 1) mercury (elemental), 2) aluminum (aluminum chloride\n        hexahydrate, aluminum hydroxide and/or aluminum lactate) or 3) palladium (sodium\n        tetrachloropalladate and/or palladium chloride) within the past 10 years.\n\n        4. Male or non-pregnant non-lactating female. Female subjects must state, at visit  one\n        that they are not pregnant, not lactating nor are they intending to become pregnant for\n        the course of the study.\n\n        5. Has understood and signed the approved Informed Consent/Assent Form, which is\n        consistent with all institutional, local and national regulations. Assent Form for all\n        minor subjects (ages 15-17) must be signed by the guardian/parent.\n\n        Exclusion Criteria:\n\n          1. Breastfeeding or pregnant or intending to become pregnant for the course of the\n             study.\n\n          2. Topical treatment with corticosteroids or other immunosuppressive agents on or near\n             the test area during the 7 days prior to inclusion in this study.\n\n          3. Systemic treatment with corticosteroids (equivalent to > 10 mg prednisone) or other\n             immunosuppressive agents during the 7 days prior to inclusion in this study. Inhaled\n             treatments are permitted.\n\n          4. Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to\n             inclusion in this study.\n\n          5. Acute dermatitis outbreak or dermatitis on or near the test area on the back.\n\n          6. Inability to comply with patch test study requirements including multiple return\n             visits and activity restrictions (e.g., protecting test panels from excess moisture\n             due to showering or vigorous activity).\n\n          7. Participation in a clinical trial of an investigational drug, treatment or device\n             other than T.R.U.E. TEST during this study or 3 weeks prior to inclusion in this\n             study.\n\n          8. An opinion of the Investigator that deems the potential subject to be non-compliant,\n             unable to return for study visits or complete the study as detailed in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028208", 
            "org_study_id": "SP12 2PM2 201"
        }, 
        "intervention": {
            "arm_group_label": "Mercury, Aluminum or Palladium Subjects", 
            "description": "T.R.U.E. Test metal allergen panels containing ascending doses of mercury, aluminum or palladium", 
            "intervention_name": "Mercury, Aluminum, Palladium", 
            "intervention_type": "Biological", 
            "other_name": "T.R.U.E. Test Mercury, Aluminum or Palladium Allergen Panel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Patch Test", 
            "Allergy Testing", 
            "Contact Dermatitis", 
            "Mercury, Aluminum or Palladium skin allergy"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "contact": {
                "last_name": "Marlene Isaksson, MD"
            }, 
            "contact_backup": {
                "last_name": "Magnus Bruze, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Malmo", 
                    "country": "Sweden", 
                    "zip": "SE-205 02"
                }, 
                "name": "Skane University Hospital Malmo"
            }, 
            "investigator": {
                "last_name": "Marlene Isaksson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study", 
        "overall_contact": {
            "email": "marlene.isaksson@skane.se", 
            "last_name": "Marlene Isaksson, MD"
        }, 
        "overall_contact_backup": {
            "email": "magnus.bruze@med.lu.se", 
            "last_name": "Magnus Bruze, MD"
        }, 
        "overall_official": {
            "affiliation": "Skane University Hospital Malmo", 
            "last_name": "Marlene Isaksson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will be patch tested with one experimental T.R.U.E. Test allergen panel containing ascending doses of either mercury, aluminum or palladium and a negative control and a second panel containing the marketed reference allergen. The panels will be worn for approximately 48 hours. Skin reactions will be assessed at 3, 4 and 21 days following application. A response is considered positive if it is graded 1+ (erythema, infiltration, discrete papules), 2+ (erythema, papules, infiltration, discrete vesicles) or 3+ (coalescing vesicles, bullous eruption) during at least one post removal visit.", 
            "measure": "Percentage of Participants who exhibit Positive Responses to each Allergen Concentration", 
            "safety_issue": "No", 
            "time_frame": "3-21 days following application"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tape irritation is graded on a 4 point scale: None (no tape irritation), Weak (faint to definite pink), Moderate (moderate erythema, definite redness) and Strong (severe erythema, very intense redness). Percentage of response will include weak, moderate and strong reactions.\nItching and Burning are graded on a 4 point scale: None (no discomfort), Weak (minimal discomfort), Moderate (definite discomfort) and Strong (significantly bothersome, possible interference with sleep or daily activity). Percentage of response will include weak, moderate and strong responses.", 
            "measure": "Percentage of Participants who exhibit Irritation (tape reaction), Itching and/or Burning Resulting from Application of the Investigational and Reference Allergen Panels", 
            "safety_issue": "Yes", 
            "time_frame": "Day 2: 48 hours after application"
        }, 
        "source": "Allerderm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allerderm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}